1. In Vivo
  2. >>Global Vision

Novasecta’s Survey

 
• By John Rountree

Novasecta carried out 20 in-depth private individual interviews with top executives from the European pharmaceutical industry.

Novasecta carried out 20 in-depth private individual interviews with top executives from the European pharmaceutical industry. The 20 companies that we covered all have pan-European and global interests. Of the interviewees, 75% were members of the corporate management team (C-suite) of their companies. Half were from companies headquartered in the UK; half were from companies headquartered in other European countries.

All of our interviews were carried out on the basis that none of the comments made would be attributed to...

Welcome to In Vivo

Create an account to read this article

Already a subscriber?

More from Global Vision

By The Numbers: Phase III Trials In China Skyrocket While Phase I Falls To Earth

 
• By Mainbayar Badarch

China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.

Navigating the GLP-1 Opportunity In China: Strategic Imperatives For Western Pharma

 
• By Jo Shorthouse

The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.

Can Italy Shake Off Its Reputation And Become A Premier Hub For Biotech?

 
• By Barnaby Pickering

Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.

Global Pharma Interest In Korea Undeterred Despite Political Roller Coaster

 
• By Jung Won Shin

Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.

More from In Vivo

BioBytes: Israeli-US Startup Introduces Platform For Accelerated Clinical Data Analysis

 
• By David Wild

A new AI-based platform is designed to condense months of clinical data analysis into minutes by translating plain language data queries into epidemiologically valid research requests.

The Dementia Disparity: Rethinking Alzheimer’s Through The Female Lens

 
• By Ian Taylor

Emerging research reveals that biological sex differences may significantly influence Alzheimer’s disease progression and treatment efficacy, underscoring the urgent need for sex-specific analysis in clinical trials and therapeutic development.

Deals Shaping The Industry, July 2025

An interactive look at pharma, medtech and diagnostics deals made during July 2025. Data courtesy of Biomedtracker.